Posts by workweek
Unwarranted Clinical Variation
Same age. Same sex. Same illness. Different treatment. This is unwarranted clinical variation; it’s care that’s not consistent with a patient’s preference or related to a patient’s underlying illness. The U.S. has a significant problem with unwarranted clinical variation, stemming from its inherent complexity. This isn’t a benign problem, though. The sequelae of such variation include…
Read MoreWalgreens Moves into Clinical Trials
Walgreens is moving into the clinical trial business. They aim to increase patient access and retention in clinical trials by redefining the patient experience. While the clinical trial arena faces tremendous obstacles in enrolling patients and ensuring they follow up, Walgreens is uniquely positioned to overcome such obstacles given their readily available tools and resources. The Deets…
Read MoreThe Rise and Fall of Cerebral
Digital mental health company Cerebral announced a new focus on value-based care and severe mental illness like substance use disorder. Their pivot from bread-and-butter conditions like ADHD is not surprising, given all of Cerebral’s drama over the past couple of months. However, Cerebral is in a pretty deep hole right now, and it will take more than a ladder…
Read MoreThe End.
Covid is still spreading through communities and is by no means “over.” However, sometime in July, the government is likely to decide whether to extend the public health emergency (PHE). If the PHE isn’t renewed, what will the implications be? Implications for Hospitals, Clinicians and Providers Reimbursement ➡️ Medicare has increased reimbursement to hospitals by 20% for…
Read MoreFast-track Too Fast?
Medicare Part B premiums will remain the highest they’ve ever been for the rest of 2022. CMS made efforts to reduce Part B premiums in response to the drama surrounding Biogen’s Alzheimer’s Disease drug Aduhelm, but operational and legal barriers prevented such efforts from succeeding. Biogen’s Timeline Within the past year: My Thoughts The FDA’s accelerated…
Read More“The Golden Age of Older Rectums”
Private equity-backed firms are buying out gastroenterology practices left and right. There are no signs of slowing down. As one investment manager said: We are in the Golden Age of older rectums. The Deets Around 10% of all 14,000 gastroenterologists in the U.S. are currently partners or employed by a private equity-backed firm. The three largest PE-backed GI groups include: GI Alliance: 650+…
Read More